A(2A) adenosine receptor antagonists - Future drugs for Parkinson's disease?

Drugs of the Future

Volumn 25, Issue 10, 2000, Pages 1043-1052

  Muller, C E ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENINE DERIVATIVE; ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE; CAFFEINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT ALKALOID; ISTRADEFYLLINE; LEVODOPA; LIGAND; MONOAMINE OXIDASE B INHIBITOR; MSX 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PYRAZOLOPYRIMIDINE DERIVATIVE; ROPINIROLE; SELEGILINE; THEOPHYLLINE; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN PROTECTION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DYSKINESIA; HUMAN; MOUSE; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; REVIEW; SYMPTOMATOLOGY;

EID: 0033639016     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.10.858696     Document Type: Review

References (101)

1. New developments in understanding the etiology of Parkinson's disease and in its treatment
2. Dopamine agonists in the treatment of Parkinson's disease - Past, present and future
3. Dopamine/glutamate interactions in Parkinson's disease
4. Adenosine A(2A) receptor antagonists as new agents for the treatment of Parkinson's disease
5. Receptors for purines and pyrimidines
6. Characterization and expression of the human A(2A) adenosine receptor gene
7. Adenosine receptor ligands - Recent developments Part I. Agonists
8. Current developments of A(2A) adenosine receptor antagonists
9. Adenosine receptor antagonists: Structures and potential therapeutic applications
10. Adenosine receptors and their modulators
11. Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors
12. Adenosine receptors: New opportunities for future drugs
13. Adenosine receptors and their ligands
14. Alkylxanthines as research tools
15. Drug distribution studies with microdialysis. II. Caffeine and theophylline in blood, brain and other tissues in rats
16. Caffeine - An atypical drug of dependence
17. Analogues of caffeine and theophylline: Effect of structural alterations on affinity at adenosine receptors
18. 2 antagonists
19. Effects of 8-phenyl and 8-cycloalkyl substituents on activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions
20. 2 affinity
21. Adenosine A(2A) antagonists with potent anti-cataleptic activity
22. 2-selective adenosine receptor antagonists
23. 2-adenosine antagonist in vitro and in vivo
24. 1 and A(2A) receptors
25. Aza-analogs of 8-styrylxanthines as A(2A)-adenosine receptor antagonists
26. (E)-1-(Heterocyclyl or cyclohexyl)-2-[1,3, 7-trisubstituted (xanthin-8yl)]ethenes as A(2a) adenosine receptor antagonists
27. Synthesis and structure-activity relationships of 3, 7-dimethyl-1-propargylxanthine derivatives, A(2A)-selective adenosine receptor antagonists
28. 1 and A(2A) receptors
29. 2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine
30. 8-(Sulfostyryl)xanthines: Water-soluble A(2A)-selective adenosine receptor antagonists
31. Configurationally stable analogs of styrylxanthines as A(2A) adenosine receptor antagonists
32. A(2A)-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand
33. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists
34. Motor effects induced by a blockade of adenosine A(2A) receptors in the caudate-putamen
35. 2 receptor regulation in the rat dopamine denervated striatum
36. 2 receptor antagonist, to rat brain membranes
37. 3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes: A new selective antagonist radiotigand for A(2A) adenosine receptors
38. Characterization of potent ligands at human recombinant adenosine receptors
39. New substituted 9-alkylpurines as adenosine receptor ligands
40. 1-Phenylpyrazolo[3,4-d]pyrimidines as adenosine antagonists: The effects of substituents at C4 and C6
41. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists
42. In vivo characterisation of ZM 241385, a selective adenosine A(2A) receptor antagonist
43. Pharmacodynamics of ZM 241385, a potent A(2a) adenosine receptor antagonist, after enteric administration in rat, cat and dog
44. 4-Amino-6-benzylamino- 1,2-dihydro-2-phenyl- 1,2, 4-triazolo[4,3-a]quinoxatin- 1one: A new highly selective A(2A) adenosine receptor antagonist
45. 1,2,4-Triazolo[4,3a]quinoxalin-1-ones: Versatile tools for the synthesis of potent and selective adenosine receptor antagonists
46. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A(2A) adenosine antagonists
47. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A(2a) adenosine receptor antagonist
48. SCH 58261: A selective A(2A) adenosine receptor antagonist
49. Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A(2A) antagonists
50. 1,2,3-Triazolo[5,4-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new class of A(2A) adenosine receptor antagonists
51. 3H]SCH58261, a new non-xanthine A(2A) adenosine receptor antagonist, to rat striatal membranes
52. 3H]ZM241385 as a radioligand at recombinant human A(2B) adenosine receptors
53. 2 receptor antagonists
54. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A(2A) receptors
55. Adenosine A(2A) antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
56. Actions of adenosine A(2A) receptor antagonist KW6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP
57. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys
58. KF17837: A novel selective adenosine A(2a) receptor antagonist with anticataleptic activity
59. Effects of SCH58261, an A(2A) receptor antagonist, on quinpirole-induced turning in 6hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake
60. Antiparkinonian activity of adenosine A(2A) antagonists in experimental models
61. The effect of theophylline on parkinsonian symptoms
62. Potential role of adenosine antagonist therapy in pathological tremor disorders
63. Adenosine receptor antagonists and Parkinson's disease: Actions of the A(2A) receptor in the striatum
64. Neuropharmacology of the adenosine A(2A) receptors
65. Pharmacology of adenosine A(2A) receptors
66. Distribution, biochemistry and function of striatal adenosine A(2A) receptors
67. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia
68. 2 receptors in stably cotransfected fibroblast cells
69. 2 receptors in Chinese hamster ovary cells co-transfected with the two receptors
70. 3 receptor agonist binding in the rat brain
71. 2 receptor-induced responses in stably transfected human neuroblastoma cells
72. 2 receptor-deficient mice by an adenosine A(2A) receptor antagonist
73. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A(2A) receptor
74. Knockouts anxious for new therapy
75. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists
76. Cerebral ischemia in gerbils: Effects of acute and chronic treatment with adenosine A(2A) receptor agonist and antagonist
77. Blockade of adenosine A2A receptors by SCH58261 results in neuroprotecrive effects in cerebral ischaemia in rats
78. Adenosine A(2A) receptors and neuroprotection
79. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases
80. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
81. 11C]KF17837, a selective adenosine A(2A) antagonist
82. Evaluation of carbon-11-labeled KF17837: A potential CNS adenosine A(2A) receptor ligand
83. 11C-methyl]KF17837 using 3-D-PET: Evaluation as a ligand for the study of adenosine A(2A) receptors
84. 2(A) receptor ligand MSX-2 with NMRI in mice
85. 11C]KF18446 with in vitro autoradiography and in vivo tissue uptake
86. 11C-labeled KF18446: A potential central nervous system adenosine A(2A) receptor ligand
87. 11]CSC as a possible tracer for mapping adenosine A(2A) receptors by PET
88. Caffeine analogs: Structure-activity relationships at adenosine receptors
89. Functional characterization of the A(2b) adenosine receptor in NIH 3T3 fibroblasts
90. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts
91. 3 adenosine receptor
92. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: Structure-activity relationships at adenosine receptors
93. Comparative pharmacology of human adenosine receptor subtypes: Characterization of stably transfected receptors in CHO cells
94. Comparison of CGS1594 3, ZM241385 and SCH58261 as antagonists at human adenosine receptors
95. The in vitropharmacology of ZM 241385, a potent, non-xanthine, A(2a)selective adenosine receptor antagonist
96. Pharmacological rationale for the clinical use of caffeine
97. Adenosine receptor activation and nociception
98. Adenosine and migraine
99. Cardiovascular pharmacology of the A(2A) adenosine receptor antagonist, SCH58261, in the rat